Arvinas Inc (ARVN)
31.44
-0.51
(-1.60%)
USD |
NASDAQ |
May 10, 16:00
31.45
+0.01
(+0.03%)
After-Hours: 20:00
Arvinas Research and Development Expense (Quarterly): 84.30M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 84.30M |
| December 31, 2023 | 95.20M |
| September 30, 2023 | 85.90M |
| June 30, 2023 | 103.40M |
| March 31, 2023 | 95.30M |
| December 31, 2022 | 98.30M |
| September 30, 2022 | 77.50M |
| June 30, 2022 | 75.30M |
| March 31, 2022 | 64.00M |
| December 31, 2021 | 61.90M |
| September 30, 2021 | 40.60M |
| June 30, 2021 | 43.00M |
| March 31, 2021 | 34.90M |
| December 31, 2020 | 33.24M |
| Date | Value |
|---|---|
| September 30, 2020 | 30.01M |
| June 30, 2020 | 23.42M |
| March 31, 2020 | 21.73M |
| December 31, 2019 | 20.42M |
| September 30, 2019 | 16.59M |
| June 30, 2019 | 16.00M |
| March 31, 2019 | 14.19M |
| December 31, 2018 | 14.56M |
| September 30, 2018 | 13.15M |
| June 30, 2018 | 10.34M |
| March 31, 2018 | 7.144M |
| December 31, 2017 | 6.690M |
| September 30, 2017 | 7.223M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
16.00M
Minimum
Jun 2019
103.40M
Maximum
Jun 2023
56.05M
Average
52.45M
Median
Research and Development Expense (Quarterly) Benchmarks
| Pfizer Inc | 2.493B |
| Bristol-Myers Squibb Co | 2.695B |
| Janux Therapeutics Inc | 12.24M |
| Geron Corp | 29.37M |
| Verastem Inc | 22.50M |